为探讨髓细胞性白血病（ｍ ｙｅｌｏｉｄ ｌｅｕｋｅｍ ｉａ）患者Ｐ－１７０ 蛋白过度表达与预后的关系，用免疫组化ＬＳＡＢ法（ｌａｂｅｌｌｅｄ ｓｔｒｅｐｔａｖｉｄｉｎ ｂｉｏｔｉｎ ａｓｓａｙ）检测６６ 例急性髓细胞性白血病（ａｃｕｔｅ ｍ ｙｅｌｏｉｄ ｌｅｕｋｅｍ ｉａ，ＡＭＬ）及２０ 例慢性髓细胞性白血病（ｃｈｒｏｎｉｃ ｍ ｙｅｌｏｉｄ ｌｅｕｋｅｍ ｉａ， ＣＭＬ）患者外周血单个核细胞的Ｐ－１７０ 蛋白表达。结果表明，初治组ＡＭＬ患者Ｐ－１７０ 表达率为２６．５％ （９／３４）；难治／复发组为６８．４％ （１３／１９），比初治组明显增高（Ｐ＜ ０．００５）；完全缓解组为２３．１％ （３／１３），与初治组差异无显著性。诱导化疗Ｐ－１７０＋ 者完全缓解（ＣＲ）率为２２．２％ （７／９），Ｐ－１７０－ 者为８０％ （２０／２５），二者差异有显著性（Ｐ＝ ０．００３６）。ＣＭＬ慢性或加速期８ 例患者无１ 例Ｐ－１７０ 表达，急变期患者Ｐ－１７０ 表达率为５０％ （６／１２），二者差异有显著性（Ｐ＝ ０．０４２）。提示Ｐ－１７０ 蛋白过度表达是髓细胞性白血病化疗耐药和不良预后的标志 To investigate the relationship between P-170 protein overexpression and prognosis in patients with myeloid leukemia, 66 cases of acute myeloid leukemia were detected by labelled streptavidin biotin assay. , AML) and P-170 protein expression in peripheral blood mononuclear cells in 20 patients with chronic myelogenous leukemia (CML). The results showed that the expression rate of P-170 was 26.5% (9/34) in AML patients in the untreated group and 68.4% (13/19) in the refractory/relapsed group, which was significantly higher than that in the untreated group (P<0). .005); The complete remission group was 23.1% (3/13), which was not significantly different from the initial treatment group. The complete remission (CR) rate of induction chemotherapy P-170+ was 22.2% (7/9), and P-170- was 80% (20/25). The difference was significant (P = 0.0036). . There was no P-170 expression in 8 patients with chronic or accelerated CML, and the expression rate of P-170 was 50% (6/12) in patients with blast crisis. There was a significant difference between the two groups (P = 0.042). Prompt that P-170 protein overexpression is a hallmark of chemotherapy resistance and poor prognosis of myelogenous leukemia